New ISACA Certification Helps Students and Career Changers Build IT Knowledge and Hands-On Skills to Thrive in IT Jobs
16.3.2021 18:12:00 EET | Business Wire | Press release
Those seeking a strong foundation in IT knowledge and hands-on experience to set themselves apart as they seek technology jobs can now earn the new Information Technology Certified Associate (ITCA) certification from global IT professional association and learning organization ISACA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005796/en/
As the need for skilled technology professionals continues to grow, the IT field presents numerous promising career paths for young professionals, recent graduates and career-changers. ISACA’s new Information Technology Certified Associate (ITCA) credential – which includes certificates in Computing Fundamentals, Networks and Infrastructure Fundamentals, Cybersecurity Fundamentals, Data Science Fundamentals and Software Development Fundamentals – prepares aspiring professionals for entry into an array of IT fields. (Graphic: Business Wire)
A dynamic addition to ISACA’s globally recognized credentials, ITCA offers students, recent graduates, those new to the IT profession or professionals seeking a career change with a flexible, hybrid format comprised of traditional knowledge-based learning and performance-based learning through live labs in a virtual environment. The certification can be achieved at one’s own pace by completing all the following modular certificates that focus on different domain areas in IT:
- Computing Fundamentals
- Networks and Infrastructure Fundamentals
- Cybersecurity Fundamentals
- Software Development Fundamentals
- Data Science Fundamentals
“A key part of ISACA’s commitment to providing tools for lifelong learning is supporting professionals at every stage of their career journey, including in that critical period at the very beginning—whether they are new graduates or professionals seeking to make a career change to IT,” says David Samuelson, ISACA CEO. “We are proud to be able to serve this new generation of IT professionals and thought leaders, including those transitioning their careers due to the pandemic, by helping them differentiate and elevate themselves as they enter the job market and start their careers.”
With ITCA, young professionals, students or recent graduates with degrees in IT or computer science, and those seeking a job change can prepare themselves for in-demand jobs like computer systems administrator, technical support specialist, database administrator, systems engineer, applications developer, front-end web developer, and quality assurance analyst. The certification can also serve more experienced audit, security or governance professionals looking to enhance their understanding of foundational IT concepts.
“Working within the IT industry presents so many amazing opportunities for recent graduates, young professionals and career-changers,” says Daisy Jardine-Viner, recruitment specialist, NDK Infosec. “It’s a constantly evolving and in-demand hiring environment that offers the chance to work at the forefront of technology.”
The ITCA program offers study guides, self-paced training courses, performance-based labs, and exams for each certificate, available at discounted rates to ISACA members. Once all five exams are completed, the candidate can apply to become ITCA certified.
For more information about ITCA, visit www.isaca.org/credentialing/itca. Learn more about ISACA’s other credentials at www.isaca.org/credentialing.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has been equipping individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005796/en/
Contact information
Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
